PROCEPT BioRobotics (PRCT) Operating Leases (2020 - 2026)

PROCEPT BioRobotics (PRCT) has 7 years of Operating Leases data on file, last reported at $26.3 million in Q1 2026.

• Quarterly Operating Leases fell 7.0% year-over-year to $26.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.3 million (down 7.0% YoY) and the FY2025 annual result came in at $24.7 million, down 8.24% from the prior year.
• Operating Leases grew to $26.3 million in Q1 2026 per PRCT's latest filing, from $24.7 million in the prior quarter.
• Across five years, Operating Leases topped out at $49.2 million in Q3 2023 and bottomed at $829000.0 in Q2 2022.
• The 5-year median for Operating Leases is $26.3 million (2026), against an average of $25.1 million.
• The widest annual swing landed in 2022, when Operating Leases tumbled 53.86%; it then surged 3457.18% in 2023.
• Tracing PRCT's Operating Leases over 5 years: stood at $22.7 million in 2022, then climbed by 15.34% to $26.2 million in 2023, then gained by 2.62% to $26.9 million in 2024, then fell by 8.24% to $24.7 million in 2025, then climbed by 6.81% to $26.3 million in 2026.
• Per Business Quant, the three latest PRCT Operating Leases figures stand at $26.3 million (Q1 2026), $24.7 million (Q4 2025), and $25.2 million (Q3 2025).

Peer Comparison